Dopaminergic reward system: A short integrative review

International Archives of Medicine

Volumn 3, Issue 1, 2010, Pages

  Arias Carrián, Oscar ^a,b   Stamelou, Maria ^b   Murillo Rodríguez, Eric ^c   Menéndez Gonzlez, Manuel ^d   Pöppel, Ernst ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Escuela de Medicina   (Mexico)

^d HOSPITAL ÁLVAREZ BUYLLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE;

BEHAVIOR DISORDER; BRAIN FUNCTION; DEGENERATIVE DISEASE; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; HUMAN; LEARNING; MEMORY CONSOLIDATION; NEUROTRANSMISSION; NUCLEUS ACCUMBENS; PATHOLOGICAL GAMBLING; PUTAMEN; REVIEW; VENTRAL TEGMENTUM;

EID: 77957321990     PISSN: None     EISSN: 17557682     Source Type: Journal    
DOI: 10.1186/1755-7682-3-24     Document Type: Review

References (76)

1. The occurrence, distribution and physiological role of catecholamines in the nervous system. A Carlsson, Pharmacological reviews 1959 11 2, Part 2 490 493 13667431
2. [Decreased homovanillic acid concentration in the brain in parkinsonian subjects as an expression of a disorder of central dopamine metabolism]. H Bernheimer O Hornykiewicz, Klinische Wochenschrift 1965 43 13 711 715 10.1007/BF01707066 5826380
3. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. H Bernheimer W Birkmayer O Hornykiewicz K Jellinger F Seitelberger, Journal of the neurological sciences 1973 20 4 415 455 10.1016/0022-510X(73)90175-5 4272516
4. Reward system and addiction: what dopamine does and doesn't do. G Di Chiara V Bassareo, Current opinion in pharmacology 2007 7 1 69 76 10.1016/j.coph.2006.11.003 17174602
5. The neurobiology of addictive disorders. S Ross E Peselow, Clinical neuropharmacology 2009 32 5 269 276 10.1097/WNF.0b013e3181a9163c 19834992
6. Dopamine, learning, and reward-seeking behavior. O Arias-Carrion E Poppel, Acta neurobiologiae experimentalis 2007 67 4 481 488 18320725
7. The molecular biology of memory storage: a dialog between genes and synapses. ER Kandel, Bioscience reports 2001 21 5 565 611 10.1023/A: 1014775008533 12168768
8. How the brain translates money into force: a neuroimaging study of subliminal motivation. M Pessiglione L Schmidt B Draganski R Kalisch H Lau RJ Dolan CD Frith, Science (New York, NY) 2007 316 5826 904 906
9. Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. M Pessiglione B Seymour G Flandin RJ Dolan CD Frith, Nature 2006 442 7106 1042 1045 10.1038/nature05051 16929307
10. Subjective neuronal coding of reward: temporal value discounting and risk. W Schultz, The European journal of neuroscience 31 12 2124 2135 10.1111/j.1460-9568.2010.07282.x 20497474
11. Neural basis of utility estimation. P Shizgal, Current opinion in neurobiology 1997 7 2 198 208 10.1016/S0959-4388(97)80008-6 9142755
12. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? KC Berridge TE Robinson, Brain research 1998 28 3 309 369 10.1016/S0165-0173(98)00019-8 (Pubitemid 29012677)
13. The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. S Ikemoto J Panksepp, Brain research 1999 31 1 6 41 10.1016/S0165-0173(99)00023-5 (Pubitemid 30009611)
14. A top-down perspective on dopamine, motivation and memory. AG Phillips G Vacca S Ahn, Pharmacology, biochemistry, and behavior 2008 90 2 236 249 10.1016/j.pbb.2007.10.014 18045671
15. Dopamine and reward: the anhedonia hypothesis 30 years on. RA Wise, Neurotoxicity research 2008 14 2-3 169 183 10.1007/BF03033808 19073424
16. Dopamine neuron systems in the brain: an update. A Bjorklund SB Dunnett, Trends in neurosciences 2007 30 5 194 202 10.1016/j.tins.2007.03.006 17408759
17. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains. Y Smith R Villalba, Mov Disord 2008 23 Suppl 3 534 547 10.1002/mds.22027 18781680
18. High-level levodopa therapy in Parkinson's disease: five years later. A Barbeau, Transactions of the American Neurological Association 1974 99 160 163 4463526
19. Electrophysiological studies of neurons in the ventral tegmental area of Tsai. CY Yim GJ Mogenson, Brain Res 1980 181 2 301 313 10.1016/0006-8993(80) 90614-9 7350968
20. BOLD responses reflecting dopaminergic signals in the human ventral tegmental area. K D'Ardenne SM McClure LE Nystrom JD Cohen, Science (New York, NY) 2008 319 5867 1264 1267
21. Forebrain substrates of reward and motivation. RA Wise, The Journal of comparative neurology 2005 493 1 115 121 10.1002/cne.20689 16254990
22. Dopamine, learning and motivation. RA Wise, Nature reviews 2004 5 6 483 494 10.1038/nrn1406 15152198
23. Etiopathogenesis of Parkinson disease: a new beginning? L Weidong C Shen J Jankovic, Neuroscientist 2009 15 1 28 35 10.1177/1073858408319974 19008336
24. Cholinergic interneuron characteristics and nicotinic properties in the striatum. FM Zhou CJ Wilson JA Dani, Journal of neurobiology 2002 53 4 590 605 10.1002/neu.10150 12436423
25. Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. FM Zhou C Wilson JA Dani, Neuroscientist 2003 9 1 23 36 10.1177/1073858402239588 12580337
26. Dopamine receptors: from structure to function. C Missale SR Nash SW Robinson M Jaber MG Caron, Physiological reviews 1998 78 1 189 225 9457173
27. Structure and function of dopamine receptors. D Vallone R Picetti E Borrelli, Neuroscience and biobehavioral reviews 2000 24 1 125 132 10.1016/S0149-7634(99)00063-9 10654668
28. In vivo imaging of brain dopaminergic neurotransmission system in small animals with high-resolution single photon emission computed tomography. H Saji Y Iida H Kawashima M Ogawa Y Kitamura T Mukai S Shimazu F Yoneda, Anal Sci 2003 19 1 67 71 10.2116/analsci.19.67 12558026
29. Dopamine receptors and brain function. M Jaber SW Robinson C Missale MG Caron, Neuropharmacology 1996 35 11 1503 1519 10.1016/S0028-3908(96)00100-1 9025098
30. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders. NP Verhoeff, Psychopharmacology 1999 147 3 217 249 10.1007/s002130051163 10639681
31. Neurodegenerative movement disorders: the contribution of functional imaging. P Piccini, Current opinion in neurology 2004 17 4 459 466 10.1097/01.wco.0000137538.84115.3c 15247543
32. Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. SR Sesack DB Carr N Omelchenko A Pinto, Annals of the New York Academy of Sciences 2003 1003 36 52 10.1196/annals.1300.066 14684434
33. The ability of the mesocortical dopamine system to operate in distinct temporal modes. CC Lapish S Kroener D Durstewitz A Lavin JK Seamans, Psychopharmacology 2007 191 3 609 625 10.1007/s00213-006-0527-8 17086392
34. Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. BJ Venton H Zhang PA Garris PE Phillips D Sulzer RM Wightman, Journal of neurochemistry 2003 87 5 1284 1295 10.1046/j.1471-4159.2003.02109.x 14622108
35. Getting formal with dopamine and reward. W Schultz, Neuron 2002 36 2 241 263 10.1016/S0896-6273(02)00967-4 12383780
36. Behavioral dopamine signals. W Schultz, Trends in neurosciences 2007 30 5 203 210 10.1016/j.tins.2007.03.007 17400301
37. Multiple dopamine functions at different time courses. W Schultz, Annual review of neuroscience 2007 30 259 288 10.1146/annurev.neuro.28.061604.135722 17600522
38. Adult neurogenesis and Parkinson's disease. O Arias-Carrion N Freundlieb WH Oertel GU Hoglinger, CNS & neurological disorders drug targets 2007 6 5 326 335
39. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. R Cools, Neuroscience and biobehavioral reviews 2006 30 1 1 23 10.1016/j.neubiorev.2005.03.024 15935475
40. Progression of Parkinson's disease in the clinical phase: potential markers. W Maetzler I Liepelt D Berg, Lancet neurology 2009 8 12 1158 1171 10.1016/S1474-4422(09)70291-1 19909914
41. Dopamine and the regulation of cognition and attention. A Nieoullon, Progress in neurobiology 2002 67 1 53 83 10.1016/S0301-0082(02)00011-4 12126656
42. The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome. WR Gibb CQ Mountjoy DM Mann AJ Lees, Journal of neurology, neurosurgery, and psychiatry 1989 52 2 193 200 10.1136/jnnp.52.2.193 2539435
43. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Y Okubo T Suhara K Suzuki K Kobayashi O Inoue O Terasaki Y Someya T Sassa Y Sudo E Matsushima,, et al. Nature 1997 385 6617 634 636 10.1038/385634a0 9024661
44. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. A Abi-Dargham H Moore, Neuroscientist 2003 9 5 404 416 10.1177/1073858403252674 14580124
45. Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us? A Abi-Dargham, World Psychiatry 2003 2 3 166 171 16946930
46. Dopamine and the origins of human intelligence. FH Previc, Brain and cognition 1999 41 3 299 350 10.1006/brcg.1999.1129 10585240
47. Effects of bromocriptine on human subjects depend on working memory capacity. DY Kimberg M D'Esposito MJ Farah, Neuroreport 1997 8 16 3581 3585 10.1097/00001756-199711100-00032 9427330
48. Evidence that appetitive responses for dehydration and food-deprivation are learned. MA Changizi RM McGehee WG Hall, Physiology & behavior 2002 75 3 295 304
49. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. H Hall G Sedvall O Magnusson J Kopp C Halldin L Farde, Neuropsychopharmacology 1994 11 4 245 256 7531978
50. Dissociation of Pavlovian and instrumental incentive learning under dopamine antagonists. A Dickinson J Smith J Mirenowicz, Behavioral neuroscience 2000 114 3 468 483 10.1037/0735-7044.114.3.468 10883798
51. Dopamine, time, and impulsivity in humans. A Pine T Shiner B Seymour RJ Dolan, J Neurosci 30 26 8888 8896 10.1523/JNEUROSCI.6028-09.2010 20592211
52. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. G Di Chiara A Imperato, Proceedings of the National Academy of Sciences of the United States of America 1988 85 14 5274 5278 10.1073/pnas.85.14.5274 2899326
53. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. MF Olive HN Koenig MA Nannini CW Hodge, J Neurosci 2001 21 23 C184 11717387
54. Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism. Z Lin GR Uhl, Molecular pharmacology 2002 61 4 885 891 10.1124/mol.61.4.885 11901228
55. Trafficking of dopamine transporters in psychostimulant actions. NR Zahniser A Sorkin, Seminars in cell & developmental biology 2009 20 4 411 417
56. Regulation of dopamine transporter trafficking by intracellular amphetamine. KM Kahlig BJ Lute Y Wei CJ Loland U Gether JA Javitch A Galli, Molecular pharmacology 2006 70 2 542 548 10.1124/mol.106.023952 16684900
57. The role of GABA(A) receptors in the acute and chronic effects of ethanol: a decade of progress. S Kumar P Porcu DF Werner DB Matthews JL Diaz-Granados RS Helfand AL Morrow, Psychopharmacology 2009 19455309
58. Low doses of ethanol inhibit the firing of neurons in the substantia nigra, pars reticulata: a GABAergic effect? G Mereu GL Gessa, Brain Res 1985 360 1-2 325 330 10.1016/0006-8993(85)91249-1 3000533
59. Pharmacogenetic treatments for drug addiction: alcohol and opiates. CN Haile TA Kosten TR Kosten, The American journal of drug and alcohol abuse 2008 34 4 355 381 10.1080/00952990802122564 18584566
60. Pharmacotherapy of addictions. MJ Kreek KS LaForge E Butelman, Nat Rev Drug Discov 2002 1 9 710 726 10.1038/nrd897 12209151
61. Dopamine depletion reorganizes projections from the nucleus accumbens and ventral pallidum that mediate opioid-induced motor activity. L Churchill MA Klitenick PW Kalivas, J Neurosci 1998 18 19 8074 8085 9742174
62. Rats self-administer intravenous nicotine delivered in a novel smoking-relevant procedure: effects of dopamine antagonists. RE Sorge PB Clarke, The Journal of pharmacology and experimental therapeutics 2009 19448141
63. Hypothesis that mesolimbic dopamine (DA) plays a key role in mediating the reinforcing effects of drugs of abuse as well as the rewarding effects of ingestive behaviors. RB Rothman T Gendron P Hitzig, Journal of substance abuse treatment 1994 11 3 273 275 10.1016/0740-5472(94)90086-8 8072057
64. Role of the ERK/MSK1 signalling pathway in chromatin remodelling and brain responses to drugs of abuse. K Brami-Cherrier E Roze JA Girault S Betuing J Caboche, Journal of neurochemistry 2009 108 6 1323 1335 10.1111/j.1471-4159. 2009.05879.x 19183268
65. Single dose of morphine produced a prolonged effect on dopamine neuron activities. D Zhang H Zhang GZ Jin K Zhang X Zhen, Molecular pain 2008 4 57 10.1186/1744-8069-4-57 19014677
66. Review. The incentive sensitization theory of addiction: some current issues. TE Robinson KC Berridge, Philosophical transactions of the Royal Society of London 2008 363 1507 3137 3146 10.1098/rstb.2008.0093 18640920
67. Affective neuroscience of pleasure: reward in humans and animals. KC Berridge ML Kringelbach, Psychopharmacology 2008 199 3 457 480 10.1007/s00213-008-1099-6 18311558
68. The debate over dopamine's role in reward: the case for incentive salience. KC Berridge, Psychopharmacology 2007 191 3 391 431 10.1007/s00213-006-0578-x 17072591
69. Differential responsiveness to cocaine in C57BL/6J and DBA/2J mice. BA Rocha LA Odom BA Barron R Ator SA Wild MJ Forster, Psychopharmacology 1998 138 1 82 88 10.1007/s002130050648 9694530
70. C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice. RK McNamara B Levant B Taylor R Ahlbrand Y Liu JR Sullivan K Stanford NM Richtand, Neuroscience 2006 143 1 141 153 10.1016/j.neuroscience.2006.07.015 16938406
71. Changes in serotonin and norepinephrine uptake sites after chronic cocaine: pre- vs. post-withdrawal effects. T Belej D Manji S Sioutis HM Barros JN Nobrega, Brain Res 1996 736 1-2 287 296 10.1016/0006-8993(96)00713-5 8930335
72. Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment. BA Johnson, CNS drugs 2004 18 15 1105 1118 10.2165/00023210-200418150-00005 15581381
73. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. BA Johnson, Biochemical pharmacology 2008 75 1 34 56 10.1016/j.bcp.2007.08.005 17880925
74. Dopaminergic modulation of cognitive control: distinct roles for the prefrontal cortex and the basal ganglia. M van Schouwenburg E Aarts R Cools, Current pharmaceutical design 16 18 2026 2032 10.2174/138161210791293097 20370667
75. Neural mechanisms of addiction: the role of reward-related learning and memory. SE Hyman RC Malenka EJ Nestler, Annual review of neuroscience 2006 29 565 598 10.1146/annurev.neuro.29.051605.113009 16776597
76. Two types of dopamine neuron distinctly convey positive and negative motivational signals. M Matsumoto O Hikosaka, Nature 2009 459 7248 837 841 10.1038/nature08028 19448610